Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aldeyra Therapeutics Inc ALDX

Healthcare Biotechnology
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.


NDAQ:ALDX - Post by User

Aldeyra Therapeutics Inc
Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Post by AviseAnalyticson Jul 19, 2022 8:21am
172 Views
Post# 34833736

WILL ALDEYRA HIT THE BULL’S EYE IN DRY EYE?

WILL ALDEYRA HIT THE BULL’S EYE IN DRY EYE?
$ALDX 
 
Excited to share our latest coverage on Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) which announced positive results from the Phase 3 tranquility trial. The Company is scheduled to meet the FDA for a Type B Pre-NDA meeting in Q3, 2022, with a potential NDA submission likely to follow.
 
 
https://www.aviseanalytics.com/will-aldeyra-hit-the-bulls-eye-in-dry-eye/
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities